A groundbreaking immunotherapy candidate, now in clinical trials, offers a powerful dual response against cancer. This small molecule increases the activity of immune cells while making tumors more susceptible to immune attack. Developed by researchers...

Researchers from the Broad, Abbvie, and Calico Life Sciences have developed a new cancer immunotherapy candidate — now being tested in an early-stage clinical trial — that may provoke a potent response in both cancer and immune cells. Project leaders...